Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study ; volume:45 ; number:1 ; day:30 ; month:6 ; year:2023 ; pages:1-10 ; date:12.2023
Maxillofacial plastic and reconstructive surgery ; 45, Heft 1 (30.6.2023), 1-10, 12.2023
- Urheber
-
Kang, Ji-Yeon
Kim, Sang-Yup
Lim, Jae-Seok
Kim, Jwa-Young
Jin, Ga-Youn
Lee, Yeon-Jung
Lee, Eun-Young
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40902-023-00391-9
- URN
-
urn:nbn:de:101:1-2023092911343396811149
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kang, Ji-Yeon
- Kim, Sang-Yup
- Lim, Jae-Seok
- Kim, Jwa-Young
- Jin, Ga-Youn
- Lee, Yeon-Jung
- Lee, Eun-Young
- SpringerLink (Online service)
Ähnliche Objekte (12)
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
JAW
Aneurysmal bone cyst: results of an off label treatment with Denosumab
Radiological findings of denosumab treatment for giant cell tumours of bone
Monostotic fibrous dysplasia of jaw bones: a case series
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
JAW
Aneurysmal bone cyst: results of an off label treatment with Denosumab
Radiological findings of denosumab treatment for giant cell tumours of bone
Monostotic fibrous dysplasia of jaw bones: a case series
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
JAW
Aneurysmal bone cyst: results of an off label treatment with Denosumab
Radiological findings of denosumab treatment for giant cell tumours of bone